CETROTIDE 0.25

1 of 1

Merck Serono Ltd.

www.merckserono.co.il

18 Kishon St.

Yavne, Israel 81220

Tel: +972 8 9382610

Fax: +972 8 9403152

office.israel@merckgroup.com

רבמצד

2018

Cetrotide 0.25, Powder and Solvent for Solution for Injection

דייטורטצ

0.25

,

הקרזהל הסימת תנכהל סממו הקבא

Cetrorelix (as acetate) 0.25 mg/vial

ת/חקור ,ה/אפור יאופר תווצו

,םידבכנ

ןולעה יכ םכעידוהל םישקבמ ונא ןכרצל

רישכתה לש

Cetrotide 0.25

ןכדוע

:תורשואמה תויוותהה

Prevention of premature ovulation in patients undergoing a controlled ovarian

stimulation, followed by oocyte pick-up and assisted reproductive techniques.

ןולעב םייונישה ןכרצל

"דייטורטצ קירזהלו סימהל דציכ תוארוה" ףיעסב םניה

ףיעסב

ןוקובקבבש הפורתה תלוכתב קרזמה לש שדחמ יולימ

תא תונידעב יכשמ ,זאו .הטמ יפלכ הנפי ימוגה רגוסש ךכ ןוקובקבה תא יכפה

בואשל תנמ לע תאז ,הרוחא קרזמה תנכוב תכשמ תועטבו הדימב .קרזמה ךותמ הנכובה תא ירמגל הצוחה ךושמל אל ידפקה .קרזמה ךותל ןוקובקבהמ הפורתה תא דיפקה ןכ לע .הלש תוילירטסה תא הדביא וז הנמ ,קרזמה ךותמ הנכובה תא הצוחה השדח הנמ יניכהו התוא ךילשהל י

בלשמ יליחתה

שי יכ ןייצל

.הרמחה םיווהמ םניא םייוניש ולעב ןייעל שי אלמה עדימל

רשואש יפכ

.תואירבה דרשמ ידי לע

ןולעה ןכרצל

חלשנ

םוסרפל

לבקל ןתינו ,תואירבה דרשמ רתאבש תופורתה רגאמב

ו

לעבל הינפ ידי לע ספדומ ןושיקה 'חר ,מ"עב ונורס קרמ םושירה

18

הנבי ,

81220

'לט ,

09-9510737

הכרבב

סקופ תירו

הנוממ תחקור

Prescribing Information

Cetrotide

®

0.25

1.

NAME OF THE MEDICINAL PRODUCT

Cetrotide

0.25 mg powder and solvent for solution for injection

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 0.25 mg cetrorelix (as acetate).

After reconstitution with the solvent provided, each mL of the solution contains 0.25 mg cetrorelix.

For the full list of excipients, see section 6.1.

3.

PHARMACEUTICAL FORM

Powder and solvent for solution for injection.

Appearance of the powder: white lyophilisate

Appearance of the solvent: clear and colourless solution

The pH of the reconstituted solution is 4.0 – 6.0

4.

CLINICAL PARTICULARS

4.1

Therapeutic indications

Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte

pick-up and assisted reproductive techniques.

In clinical trials Cetrotide was used with human menopausal gonadotropin (HMG), however, limited

experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy.

4.2

Posology and method of administration

Cetrotide® should only be prescribed by a specialist experienced in this field.

Posology

The first administration of Cetrotide should be performed under the supervision of a physician and under

conditions where treatment of possible allergic/pseudo-allergic reactions (including life-threatening

anaphylaxis) is immediately available. The following injections may be self-administered as long as the

patient is made aware of the signs and symptoms that may indicate hypersensitivity, the consequences of such

a reaction and the need for immediate medical intervention.

The contents of 1 vial (0.25 mg cetrorelix) are to be administered once daily, at 24 h intervals, either in the

morning or in the evening. Following the first administration, it is advised that the patient be kept under

medical supervision for 30 minutes to ensure there is no allergic/pseudo-allergic reaction to the injection.

Elderly

There is no relevant use of Cetrotide in the geriatric population.

Paediatric population

There is no relevant use of Cetrotide in the paediatric population.

Method of administration

Cetrotide is for subcutaneous injection into the lower abdominal wall.

The injection site reactions may be minimised by rotating the injection sites, delaying injection at the same

site and injecting the product in a slow rate to facilitate the progressive absorption of the product.

Administration in the morning: Treatment with Cetrotide should commence on day 5 or 6 of ovarian

stimulation (approximately 96 to 120 hours after start of ovarian stimulation) with urinary or recombinant

gonadotropins and is to be continued throughout the gonadotropin treatment period including the day of

ovulation induction.

Administration in the evening: Treatment with Cetrotide should commence on day 5 of ovarian stimulation

(approximately 96 to 108 hours after start of ovarian stimulation) with urinary or recombinant gonadotropins

and is to be continued throughout the gonadotropin treatment period until the evening prior to the day of

ovulation induction.

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

4.3

Contraindications

Cetrorelix is not to be used in the presence of any of the conditions listed below:

Hypersensitivity to the active substance or any structural analogues of gonadotropin-releasing hormone

(GnRH), extrinsic peptide hormones or to any of the excipients listed in section 6.1.

During pregnancy and lactation.

Patients with severe renal impairment.

4.4

Special warnings and precautions for use

Allergic conditions

Cases of allergic/pseudoallergic reactions, including life-threatening anaphylaxis with the first dose have been

reported (see section 4.8).

Special care should be taken in women with signs and symptoms of active allergic conditions or known

history of allergic predisposition. Treatment with Cetrotide is not advised in women with severe allergic

conditions.

Ovarian Hyperstimulation Syndrome (OHSS)

During or following ovarian stimulation an ovarian hyperstimulation syndrome can occur. This event must be

considered as an intrinsic risk of the stimulation procedure with gonadotropins.

An OHSS should be treated symptomatically, e.g. with rest, intravenous electrolytes/colloids and heparin

therapy.

Luteal phase support should be given according to the reproductive medical centre´s practice.

Repeated ovarian stimulation procedure

There is limited experience up to now with the administration of cetrorelix during a repeated ovarian

stimulation procedure. Therefore cetrorelix should be used in repeated cycles only after a careful benefit/risk

evaluation.

Congenital anomalies

The prevalence of congenital anomalies after the use of assisted reproductive technologies (ART) with or

without GnRH antagonists may be slightly higher than after spontaneous conceptions although it is unclear

whether this is related to factors inherent to the couple's infertility or the ART procedures.

Limited data from clinical follow-up studies in 316 newborns of women administered cetrorelix for infertility

treatments suggest that cetrorelix does not increase the risk of congenital anomalies in the offsprings.

Hepatic impairment

Cetrorelix has not been studied in patients with hepatic impairment and caution is therefore

warranted.

Renal impairment

Cetrorelix has not been studied in patients with renal impairment and caution is therefore warranted.

Cetrorelix is contraindicated in patients with severe renal impairment (see section 4.3).

4.5

Interaction with other medicinal products and other forms of interaction

No formal drug-drug interaction studies have been performed with cetrorelix.

In vitro

investigations have

shown that interactions are unlikely with medicinal products that are metabolised by cytochrome P450 or

glucuronised or conjugated in some other way. However, the possibility of interactions with gonadotropins or

medicinal products that may induce histamine release in susceptible individuals, cannot be totally excluded.

4.6

Fertility, pregnancy and lactation

Pregnancy and breast-feeding

Cetrotide is not intended to be used during pregnancy and lactation (see section 4.3).

Fertility

Studies in animals have indicated that cetrorelix exerts a dose related influence on fertility, reproductive

performance and pregnancy. No teratogenic effects occurred when the medicinal product was administered

during the sensitive phase of gestation.

4.7

Effects on ability to drive and use machines

Cetrotide has no or negligible influence on the ability to drive and use machines.

4.8

Undesirable effects

Summary of the safety profile

The most commonly reported adverse reactions are local injection site reactions such as erythema, swelling

and pruritus that are usually transient in nature and mild in intensity. In clinical trials, these effects were

observed with a frequency of 9.4% following multiple injections of Cetrotide 0.25 mg.

Mild to moderate OHSS (WHO grade I or II) have been commonly reported and should be considered as an

intrinsic risk of the stimulation procedure. Inversely, severe OHSS remains uncommon.

Uncommonly, cases of hypersensitivity reactions including pseudo-allergic/anaphylactoid reactions have been

reported.

List of adverse reactions

The adverse reactions reported below are classified according to frequency of occurrence as follows:

Very Common (≥ 1/10), Common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to

< 1/1,000), very rare (< 1/10,000).

Immune system disorders

Uncommon:

Systemic allergic/pseudo-allergic reactions including life-threatening anaphylaxis.

Nervous system disorders

Uncommon:

Headache

Gastrointestinal disorders

Uncommon:

Nausea

Reproductive system and breast disorders

Common:

Mild to moderate OHSS (WHO grade I or II) can occur which is an intrinsic risk of the

stimulation procedure (see section 4.4).

Uncommon:

Severe OHSS (WHO grade III).

General disorders and administration site conditions

Common:

Local reactions at the injection site (e.g. erythema, swelling and pruritus).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows

continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National

Regulation by using an online form

http://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.gov.il

4.9

Overdose

Overdosage in humans may result in a prolonged duration of action but is unlikely to be associated with acute

toxic effects.

In acute toxicity studies in rodents non-specific toxic symptoms were observed after intraperitoneal

administration of cetrorelix doses more than 200 times higher than the pharmacologically effective dose after

subcutaneous administration.

5.

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties

Pharmacotherapeutic group: anti-gonadotropin-releasing hormones, ATC code: H01CC02.

Mechanism of action

Cetrorelix is a luteinising hormone releasing hormone (LHRH) antagonist. LHRH binds to membrane

receptors on pituitary cells. Cetrorelix competes with the binding of endogenous LHRH to these receptors.

Due to this mode of action, cetrorelix controls the secretion of gonadotropins (LH and FSH).

Cetrorelix dose-dependently inhibits the secretion of LH and FSH from the pituitary gland. The onset of

suppression is virtually immediate and is maintained by continuous treatment, without initial stimulatory

effect.

Clinical efficacy and safety

In females, cetrorelix delays the LH surge and consequently ovulation. In women undergoing ovarian

stimulation the duration of action of cetrorelix is dose dependent. At a dose of 0.25 mg per injection repeated

injections every 24 hours will maintain the effect of cetrorelix.

In animals as well as in humans, the antagonistic hormonal effects of cetrorelix were fully reversible after

termination of treatment.

5.2

Pharmacokinetic properties

Absorption

The absolute bioavailability of cetrorelix after subcutaneous administration is about 85%.

Distribution

The volume of distribution (V

) is 1.1 L x kg

Elimination

The total plasma clearance and the renal clearance are 1.2 mL x min

x kg

and 0.1 mL x min

x kg

respectively.

The mean terminal half-lives following intravenous and subcutaneous administration are about 12 h and 30 h,

respectively, demonstrating the effect of absorption processes at the injection site.

Linearity

The subcutaneous administration of single doses (0.25 mg to 3 mg cetrorelix) and also daily dosing over

14 days show linear kinetics.

5.3

Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety

pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

No target organ toxicity could be observed from acute, subacute and chronic toxicity studies in rats and dogs

following subcutaneous administration of cetrorelix. No signs of medicinal product-related local irritation or

incompatibility were noted in dogs after intravenous, intra-arterial and paravenous injection when cetrorelix

was administered in doses clearly above the intended clinical use in man.

Cetrorelix showed no mutagenic or clastogenic potential in gene and chromosome mutation assays.

6.

PHARMACEUTICAL PARTICULARS

6.1

List of excipients

Powder:

Mannitol

Solvent:

Water for injections

6.2

Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section

6.6.

6.3

Shelf life

Unopened vial: 2 years

Reconstituted product: use immediately

6.4

Special precautions for storage

Store in a refrigerator (2°C – 8°C); in the original package in order to protect from light. The unopened

product may be stored in the original package at room temperature (not above 30°C) for up to three months.

This product must be at room temperature prior to injection. Remove from the refrigerator approximately

30 minutes before use.

Do not freeze or place next to the freezer compartment or a freezer pack.

6.5

Nature and contents of container

Powder: 2 ml vials (Type I glass) with a stopper (bromobutyl rubber) and flip-off aluminium cap.

1 vial contains 0.25 mg cetrorelix.

Solvent: Pre-filled syringe (Type I glass) with plunger stopper (siliconised bromobutyl rubber) and tip cap

(polypropylene and styrene butadiene rubber).

1 pre-filled syringe contains 1 ml of water for injections.

Additionally for each vial the pack contains:

1 injection needle (20 gauge)

1 hypodermic injection needle (27 gauge)

2 alcohol swabs

Pack sizes of 1 vial and 1 pre-filled syringe or 7 vials and 7 pre-filled syringes.

Not all pack sizes may be marketed.

6.6

Special precautions for disposal and other handling

This product must be at room temperature prior to injection. Remove from the refrigerator approximately

30 minutes before use.

Cetrotide should only be reconstituted with the solvent provided, using a gentle, swirling motion. Vigorous

shaking with bubble formation should be avoided.

The reconstituted solution is without particles and clear. Do not use if the solution contains particles or if the

solution is not clear.

Withdraw the entire contents of the vial. This ensures a delivery to the patient of a dose of at least 0.23 mg

cetrorelix.

The solution should be used immediately after reconstitution.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7.

REGISTRATION NO.

117 19 29780 00, 117 19 29780 01

8.

MANUFACTURER

Merck KGaA, Darmstadt, Germany

9.

REGISTRATION HOLDER

Merck Serono Ltd., 18 Hakishon St., Yavne

10.

DATE OF REVISION OF THE TEXT

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved

in April 2016, and was updated according to MOH instructions in May 2018.